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Multinuklearne džinovske stromalne ćelije u adenoidnocističnom karcinomu dojke:
prikaz bolesnice i pregled literature
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Abstract
Background. We presented an unusual case of adenoid
cystic carcinoma (ACC) of the breast with multinucleated
stromal giant cells (MSGCs). To the best of our knowledge,
the occurrence of ACC with MSGCs has not been reported
previously. MSGCs should be distinguished from other
multinucleated giant cells in breast tumors. The histogenesis
of MSGCs still remains obscure. In hope to elucidate the
histogenesis of MSGCs, we used a broad range of antibod-
ies. Case report. A 40-year-old woman presented with a
palpable lump in the subareolar location of her right breast.
Excision of the tumor was performed. At gross pathologic
examination the tumor was 20 × 15 × 15 mm in size, red-
brown and well circumscribed. The surgical margins were
positive for carcinoma and skin-sparing mastectomy with
axillary dissection was complited. Eighteen lymph nodes ex-
amined were uninvolved. Patohistological examination
showed ACC with numerous MSGCs scattered within tu-
mor stroma. Immunohistochemical studies indicated that
MSGCs are probably derived from stromal fibroblasts.
These cells showed strong reactivity only for vimentin.
Staining for histiocytic marker (CD68), as well as for epithe-
lial marker (cytokeratin), myoepithelial markers (S-100, α-
smooth muscle actin), vascular marker (CD34), hormonal
receptors (ER, PR) and HER2 in MSGCs were negative.
Conclusion. The presence of MSGCs should not alter the
prognosis of an otherwise typical breast ACC.
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Apstrakt
Uvod. Prikazana je bolesnica sa veoma retkim adenoidno-
cističnim karcinomom (ACC) dojke sa prisustvom brojnih
multinuklearnih džinovskih stromalnih ćelija (MSGC).
Prema nama dostupnim podacima iz literature do sada nije
opisan nijedan slučaj ACC sa MSGC. Ove ćelije se razli-
kuju od drugih džinovskih multinuklearnih ćelija koje se
mogu naći u tumorima dojke. Da bi otkrili poreklo MSGC
primenili smo imunohistohemijsko ispitivanje primenom
većeg broja različitih antitela. Prikaz bolesnice. Prikazali
smo ženu, staru 40 godina, sa palpabilnim tumorom suba-
reolarne regije desne dojke. Urađena je ekscizija tumora.
Makroskopski, tumor bio je promera 20 × 15 × 15 mm,
crvenobraon boje i jasno ograničen. Zbog pozitivnih rese-
kcionih ivica, urađena je mastektomija sa disekcijom aksile.
Osamnaest pregledanih limfnih nodusa nije imalo metasta-
ze. Patohistološki je potvrđen ACC sa brojnim MSGC
unutar strome tumora. Imunohistohemijskim ispitivanjem
utvrđeno je da MSGC verovatno vode poreklo od fibrob-
lasta strome. Ove ćelije su ispoljile jako pozitivnu reakciju
samo na vimentin. Imunohistohemijska bojenja na histio-
citne (CD68), epitelne (cytokeratin), mioepitelne (S-100, α-
smooth muscle actin) i vaskularne (CD34) markere, kao i na
hormonske receptore (ER, PR) i HER2 bila su negativna u
MSGC. Zaključak. Prisustvo MSGC ne utiče na progno-
zu tipičnog ACC.
Ključne reči:
dojka, neoplazme; karcinom, adenoidni cistični; ćelije,
gigantske; prognoza.
Introduction
Adenoid cystic carcinoma (ACC) of the breast is a very
rare neoplasm accounting less than 0.1% of all invasive
breast carcinomas 
1. It is of special interest because of its fa-
vorable prognosis and distinctive histological appearance.
The clinical features are a well-circumscribed palpable mass
centrally located, which is occasionally tender on palpation.
Histologically, ACC has a distinctive biphasic pattern that
consists of true glandular lumens lined by the epithelial cell
component and pseudocystic spaces lined by basaloid myo-
epithelial cells 
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rence of ACC with multinucleated stromal giant cells
(MSGCs) has not been reported previously. Multinucleated
stromal giant cells in the breast were first described by
Rosen 
2. Despite the fact that MSGCs have been well docu-
mented in other anatomic locations, only several reports de-
scribed similar cells in both benign and malignant tumors of
the breast
 3–7. They are usually located within the stroma, with
no association with the epithelial cells. MSGCs should be dis-
tinguished from osteoclast-like giant cells, which most likely
represent reactive stromal elements of histiocytic origin 
8.
The histogenesis of MSGCs still remains obscure. We
present herein the unusual case of ACC with MSGCs. In
hopes to elucidate the histogenesis of MSGCs, we utilized a
panel of immunohistochemical markers.
Case report
A 40-year-old woman presented with a palpable lump
in the subareolar location of her right breast, with no palpa-
ble axillary adenopathy. There was no nipple discharge.
Family history was negative for breast cancer. On clinical
examination a firm nodule was suggestive for fibroadenoma.
An ultrasound scan was also compatible with a diagnosis of a
fibroadenoma. No further diagnostic attempts were made,
and local excision was performed. At gross pathologic ex-
amination the tumor was 20 × 15 × 15 mm in size, red-
brown and well circumscribed. Despite well-defined borders,
the surgical margins were positive for carcinoma. Neither
vascular nor lymphatic invasion was seen. The patient un-
derwent a skin-sparing mastectomy. Since the sentinel node
procedure was still investigational at that time, the axillary
dissection was complited. Eighteen lymph nodes examined
were uninvolved. The patient made a good recovery after
surgery. She received no adjuvant therapy and was well with
no evidence of disease 18 months later.
The obtained tissue was fixed and routinely embedded.
Laboratory paraffin sections were stained with hematoxylin-
eosin (H&E) and alcian-blue periodic acid-Schiff (AB-PAS)
techniques. Immunohistochemical analysis was performed
with the alkaline phosphatase anti-alkaline phosphatase
(APAAP) technique, using antibodies against: vimentin,
CD68, CD34, S-100, α-smooth muscle actin, cytokeratin,
estrogen receptor (ER), progesterone receptor (PR) and Her-
ceptest (DAKO, Copenhagen, Denmark).
The histological examination showed a small dark-
staining neoplastic cells in islands, containing many pseudo-
cysts filled with eosinophilic material, together with tubular
duct-like structures. Both the modified Bloom Richardson
grade and the nuclear grade of the lesion were 1. Numerous
MSGCs were relatively diffusely scattered within the tumor
stroma (Figure 1). The cells appeared to have multiple, aggre-
gated, often hyperchromatic nuclei (5 to 25). The cytoplasm of
MSGCs was eosinophilic with a coarsely granular pattern. No
mitotic figures were seen in MSGCs. The pseudocysts, which
contain amorphous basement membrane material, show posi-
tive staining for alcian-blue (Figure 2). The tumor was nega-
tive for hormonal receptors. Expression of human epidermal
growth factor receptor 2 (HER2) was also negative.
Fig. 1 – Photomicrograph demonstrates multinucleated
stromal giant cells scattered within the tumor stroma in
adenoid cystic carcinoma of the breast (H&E, 200×)
Fig. 2 – Adenoid cystic carcinoma of the breast with multi-
nucleated stromal giant cells (AB-PAS, 200×)
Despite the broad range of antibodies used to elucidate
the histogenetic origin of MSGCs, these cells showed strong
reactivity only for vimentin (Figure 3). Staining for histio-
cytic marker (CD68), as well as for epithelial marker (cyto-
keratin), myoepithelial markers (S-100, α-smooth muscle
actin), vascular marker (CD34), hormonal receptors (ER,
PR) and HER2 in MSGCs were negative.
Fig. 3 – Immunohistochemical staining shows positivity for
vimentin within the multinucleated stromal giant cells
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Discussion
The presence of MSGCs in breast tumors is a phenome-
non of uncertain significance. We reported herein the unusual
case of a rare breast neoplasm with numerous MSGCs. To the
best of our knowledge, however, no previous reports have de-
scribed ACC with MSGCs, indicating that this lesion is ex-
tremely rare. Originally, Rosen described MSGCs in otherwise
normal breast parenchyma 
2. In the series of 200 consecutive
mastectomies for carcinoma, he observed MSGCs in nine
cases. He interpreted them as a sign of probable reparative
process, possibly linked to hormonal changes.
The origin of MSGCs still remains obscure. They could
be derived from four different stem cells: fibroblastic,
epithelial, myoepithelial and histiocytic. Berean et al. 
3
thought the multinucleate giant cells in fibroadenoma were
fibroblastic in nature following immunohistochemical and
ultrastructural study. Ryska et al. 
4 assumed the positivity of
p53, in both mononuclear stromal cells and MSGCs, may
play a key role in linking together these two cell types.
Therefore, MSGCs could presumably originate from mono-
nuclear stromal cells. Powell et al. 
5 similarly thought they
were fibrohistiocytic in origin based on the finding of a con-
tinuum of morphological features ranging from small stromal
cells to the fully formed multinucleated cells. They also
demonstrated positive CD34 staining of these cells in few
cases. In contrast, Nielsen and Ladefoged 
6 concluded that
the giant cells in their case report were myoepithelial in ori-
gin, although the evidence for this was not clearly demon-
strated; no immunohistochemistry confirming this hypothesis
was performed.
It is difficult to explain the histogenesis of MSGCs. The
results of immunohistochemistry in our case of ACC indicate
that MSGCs are probably derived from stromal fibroblasts.
The MSGCs were positive only for vimentin. No signs of
histiocytic (CD68 was negative), epithelial (cytokratin was
negative) and myoepithelial (S-100 and α-smooth muscle
actin were negative) differentiation were seen in MSGCs.
Also, there was no evidence about hormonal (ER and PR), or
HER2 positivity in MSGCs.
MSGCs should be distinguished from other
multinucleated giant cells in breast tumors, such as osteo-
clast-like giant cells. The majority of invasive breast carci-
nomas with osteoclast-like giant cells have been invasive
ductal carcinoma; the most common being of the cribriforme
type. Less commonly, osteoclast-like giant cells have been
described in infiltrating lobular carcinomas, tubular, papil-
lary and rarely in association with ductal carcinoma in situ 
7.
Microscopically, osteoclast-like giant cells are indistinguish-
able from true osteoclasts and it is belived to arise from fu-
sion of stromal cells, thus having a monocyte/macrophage
origin. This finding is supported by immunohistochemistry
and electron microscopy. They frequently express histiocytic
markers, like CD68, α-1-antitrypsin or acid phosphatase 
8, 9.
The morphology of MSGCs is essentially different from os-
teoclasts and none of MSGCs in our case showed CD68
positivity. Other lesions that may contain multinucleated gi-
ant cells such as tuberculosis, sarcoidosis or granulomatous
mastitis must be included in the differential diagnosis. The
Langhans-type giant cells, as well as the foreign-body type
giant cells should be readily distinguishable from MSGCs.
Bizarre malignant giant cells have also been described in
breast carcinomas. These giant cells are easily distinguish-
able from MSGCs by their pleomorphism and immunopro-
file, indicating an epithelial (cytokeratin-positive) origin 
8.
Conclusion
Immunohistochemical studies indicated that the
MSGCs are probably derived from stromal fibroblasts. In
contrast to the more aggressive behavior of salivary gland
ACC, the prognosis for breast ACC is rather good, with a
low incidence of lymph node invasion and of distant metas-
tasis. The presence of MSGCs should not alter the prognosis
of an otherwise typical breast ACC. This indicates the prob-
able indolent nature of MSGCs.
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